Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study
Neumora Therapeutics, Inc. has initiated a Phase 1 clinical study of NMRA-898, a M4 Positive Allosteric Modulator.
NMRA-898 is structurally distinct from NMRA-861 and is the second M4 PAM in Neumora's M4 franchise, with potential best-in-class pharmacology.
- No convulsions were observed in pre-clinical studies conducted in multiple species, including rabbits.
- Neumora plans to provide a comprehensive M4 franchise update by mid-2026.
Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company redefining neuroscience drug development.
No additional quotes available.
Author's summary: Neumora starts Phase 1 study of NMRA-898.
More News
- Liam Hemsworth vs. Gabriella Brooks: Who Has the Higher Net Worth?
- Staffordshire Leader Reacts to "Squandered" Billions of Taxpayers' Money on Asylum Hotels - Staffordshire County Council Newsroom
- Budget jitters see construction forecasts plummet
- Biopic reintroduces female revolutionary hero - BusinessWorld Online
- Acting in Self-Defense – Communications of the ACM
- Pirates Listed as Potential Fit for Trent Grisham, Luis Arráez and Other Top Free Agents
- The new age of pediatric medication awareness - Express Healthcare
- The environmental impact of the 2026 World Cup
- 2 US Navy aircraft crash in South China Sea
- Wallingford deli asks for help to keep feeding people in need